Hongo H, Kosaka T, Suzuki Y, et al. - Pimozide, which targets AURKB and KIF20A, looks to be a viable medication for overcoming cabazitaxel (CBZ) resistance in castration-resistant prostate cancer (CRPC).

• Pimozide was found as a promising prospective medication for CBZ-resistant CRPC.

• On DU145CR cells, pimozide demonstrated a substantial antitumor impact.

• Furthermore, the combination of pimozide and CBZ showed a synergistic effect on DU145CR cells in vitro and in vivo.

• AURKB and KIF20A were identified as potential pimozide targets in CBZ-resistant CRPC using microarray analysis.

• When compared with a non-CBZ-resistant cell line, DU145CR had considerably higher AURKB and KIF20A expression.

• In DU145CR xenograft tumors, inhibiting AURKB and KIF20A had an antitumor impact.

• Higher AURKB and KIF20A expression was associated with a worse prognosis in the TGCA prostate cancer cohort.

• AURKB and KIF20A expression were greater in CBZ-resistant prostate cancer tissues at the institution.